Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 177Neoplasm Metastasis 142Neoplasms 136Leukemia, Myeloid, Acute 128Colorectal Neoplasms 126Breast Neoplasms 115Ovarian Neoplasms 89Melanoma 88Prostatic Neoplasms 86Recurrence 84Multiple Myeloma 81Pancreatic Neoplasms 74Squamous Cell Carcinoma of Head and Neck 72Glioblastoma 72Lung Neoplasms 70Lymphoma, Non-Hodgkin 63Myelodysplastic Syndromes 60Triple Negative Breast Neoplasms 57Glioma 53Stomach Neoplasms 52Precursor Cell Lymphoblastic Leukemia-Lymphoma 49Endometrial Neoplasms 48Carcinoma, Renal Cell 47Small Cell Lung Carcinoma 46Lymphoma, Large B-Cell, Diffuse 44Brain Neoplasms 43Carcinoma, Hepatocellular 41Sarcoma 39Lymphoma, B-Cell 39Advanced Solid Tumors 39

Interventions

enzalutamide 1darolutamide 1cabazitaxel 1apalutamide 1Prednisone 1Docetaxel 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Metastatic Castration-resistant Prostate Neoplasms × 90 days × Clear all
NCT05818683 2026-06-05

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Janssen Research & Development, LLC

Phase 1 Recruiting
300 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡